Allele: A Division of Catalyst BC

Allele’s core mission is to combine market–proven cannabis genetics with modern agricultural science with the goal of developing commercial cannabis cultivars to maximize product quality and drive financial performance. Allele sources the highest quality genetic material then, integrates genomic mapping and predictive breeding platforms, and utilizes modern tissue culture procedures to provide turnkey genetics solutions that maximize profit and minimize risk for large-scale commercial cannabinoid production.

Genetics Improvement:

Allele will work alongside your cultivation team to identify specific genetic development needs in order to design and implement propagation and breeding programs that will produce unique and proprietary cultivars, providing maximized productivity and profitability. We have developed a dynamic and growing portfolio of unique, exotic and desirable cannabis genetics that exhibit elevated levels of resin content, terpenes, and cannabinoids (THC-A, CBD, CBG, and CBC). Our cultivars have years of proven commercial viability in multiple markets utilizing many types of cultivation methods.  We will work with you to determine your company’s specific genetic needs and implement breeding programs that produce unique and proprietary cultivars that allow you to maximize productivity and profit.  By using the latest genomic mapping, laboratory grade tissue culture and micropropagation techniques we are providing science backed cannabis genetics to a modern market.

Service offerings include:

Award Winning & Proven Cannabis Genetics
Unreleased, Non-Market Exposed Cannabis Genetics
Cannabis Genetics Development
Cannabis Genetics Preservation
Micropropagation (International only)
Targeted Pollination
Seed Production
Genetics Consulting
Genetics Selection
Production Planning

Additional Resources

Consulting Services For Cannabis, Hemp, Psilocybin, and Natural Medicine

Testimonials and Public Relations

Latest Articles

Open a Cannabis Consumption Lounge in New Jersey: 2026 Guide to Compliance and Success
As of April 2026, the New Jersey cannabis market has matured into a sophisticated $4 billion powerhouse. The initial “novelty” phase has passed, and the industry is now defined by “Hospitality 2.0,” where consumption areas are becoming social anchors for local tourism in hubs like Atlantic City, Newark, and Jersey City.
New York Cannabis Lounge License: Expert Guide to Compliance and Success
The New York cannabis industry has transitioned from a volatile implementation phase into a “Pharma-Grade” era of structural maturity. As of April 2026, the state has reached a monumental economic milestone, with total reported retail sales officially surpassing $3,000,000,000. For entrepreneurs, the current frontier is the “social hospitality” sector, which is defined by high-stakes technical compliance and rigorous municipal negotiation.
The 2026 New York Execution Gap: Scaling Your Cannabis Business
The trajectory of the New York cannabis industry has transitioned from a period of experimental regulation to one of massive commercial consolidation and operational intensity. As of April 15, 2026, the state has officially matured into its role as the second-largest cannabis market in the United States, trailing only California in total economic activity and consumer demand. The primary indicator of this success is the milestone reached in early 2026, where total reported retail sales since the inception of the legal program surpassed $2.97 billion.
Regulatory Maturity and Market Dynamics: A Comprehensive Analysis of the New Jersey Cannabis Industry
The legal landscape of cannabis in New Jersey has transitioned from a period of rapid legislative enactment into an era of complex regulatory maturity and secondary market correction. Since the foundational passage of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (CREAMMA) in early 2021, the state has systematically dismantled the architecture of prohibition while constructing a highly regulated, billion-dollar industry.
Nebraska Medical Cannabis Market Strategic Report: Navigating the Regulatory Landscape and Licensing Framework 2026
The Nebraska medical cannabis industry has undergone a radical transformation from its nascent beginnings in the 2024 general election to the highly structured, albeit restrictive, regulatory environment of April 2026. This period has been characterized by intense legislative maneuvering, high-stakes licensing competitions, and a fundamental shift in the state’s administrative approach to controlled substances.
Navigating the Minnesota Social Equity and Cannabis Licensing Landscape: 2026 Comprehensive Strategic Analysis
As of April 15, 2026, the landscape is defined by the full enforcement of permanent licensure requirements. The landmark hard transition deadline of March 31, 2026, forced all temporary registrations for Lower-Potency Hemp Edible (LPHE) manufacturers and wholesalers to convert into full OCM licenses or face immediate operational shutdown.